H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 233 000 KRW -0.85% Market Closed
Market Cap: 2.9T KRW

EV/EBITDA
Enterprise Value to EBITDA

11.4
Current
14
Median
6.3
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
11.4
=
Enterprise Value
2.4T KRW
/
EBITDA
211.7B KRW
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average EV/EBITDA: 36.7
11.4
20%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 499.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.1
2-Years Forward
EV/EBITDA
9.3
3-Years Forward
EV/EBITDA
7.7